Abstract The aim of the study was to identify chromosomal regions that may harbor putative genetic variants influencing age at onset in familial late-onset Alzheimer's disease (LOAD). Data from a genome-wide scan that included genotyping of APOE were analyzed in 1,161 individuals from 209 families of Caribbean Hispanic ancestry with a mean age at onset of 73.3 years multiply affected by LOAD. Two-point and multipoint analyses were conducted using variance component methods using 376 microsatellite markers with an average intermarker distance of 9.3 cM. Family-based test of association was also conducted for the same set of markers. Age at onset of Neurogenetics (2008) 9:51-60 
Introduction
Alzheimer's disease (AD) is the most common form of dementia and the most frequent degenerative brain disorder encountered in old age. The risk of developing AD substantially increases after 65 years of age [1] . While the cause of this disease remains unknown, there is evidence for substantial genetic influence [2] [3] [4] . Mutations in three genes, amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1, PSEN2), result in an early onset, autosomal dominant form of the disease beginning in the third or fourth decade. The ɛ4 allele of apolipoprotein E (APOE) increases the risk of both sporadic and familial AD occurring later in life around the sixth decade. Each of these genes is involved in the production or processing of the amyloid β peptide, which is deposited in the brain as dense plaques that are characteristic of the disease [2] .
Over the past two decades, genetic studies of AD have relied on linkage analysis in multiply affected families, or allelic association studies of candidate genes in cohorts of unrelated AD patients and healthy, elderly controls. It is well known that gene identification for complex genetic traits, such as late-onset Alzheimer's disease (LOAD), requires far greater efforts than for Mendelian traits [5] . Several factors contribute to the difficulty, including locus heterogeneity, allelic heterogeneity, phenotypic variability, as well as influence of non-hereditary factors such as age and sex. Because of the steep increase in prevalence of LOAD with advancing age, studies have used age at onset of symptoms as a quantitative trait to identify chromosomal loci related to LOAD [6] . Covariate approaches may be useful in identifying loci in the presence of locus heterogeneity. Variants in APOE provide an example. The number of APOE-ɛ4 alleles consistently influences age at onset of LOAD [7] [8] [9] [10] [11] [12] .
Daw et al. [13] estimated that there may be as many as four additional loci contributing to the variance in age at onset of LOAD and that the magnitude of the effect from one of these genes could be similar to APOE. Indeed, analyses using age at onset of disease as a quantitative trait have yielded multiple putative loci on chromosomes 2, 7, 9, 14, 15, 20, and 21, and some of these loci were also found to be significant in the analyses of AD phenotype [14] [15] [16] [17] [18] [19] [20] . However, most of these analyses lack independent confirmation, with the exception of the locus at 14q32 [17] which is of interest because of its location near PSEN1. In the current study, we used variance component (VC) linkage analysis to attempt to confirm previous studies and to identify candidate genetic loci related to age at onset of disease in a unique cohort of families of Caribbean Hispanic ancestry multiply affected by LOAD [21, 22] .
Materials and methods
Families We included data from 1,161 individuals from 209 Caribbean Hispanic families genotyped in a family study of AD (Table 1) . These families represent 101 families from our first report of the AD genome scan [22] and 108 additional families used in the expanded second genome scan [21] . The recruitment strategy and detailed characteristics of the participants have been described previously [21] . Briefly, multiple sources were used to recruit families. We recruited from clinics in the Dominican Republic and Puerto Rico, as well as the Alzheimer's Disease Research Center Memory Disorders Clinic at Columbia University in New York City, which includes a large number of Hispanic patients. To augment family recruitment, we also advertised in local newspapers and media in Dominican Republic, Puerto Rico, and New York. In addition, we recruited probands identified in an epidemiological study in northern Manhattan when the informant reported family members with dementia. The pedigrees were of variable complexity. The majority of families consisted of probands with AD and their siblings. However, when more distant relatives of probandsprimarily aunts, uncles, or cousins-were affected with AD, all available relatives from that branch as well as individuals linking the two branches of the pedigree were studied.
The Institutional Review Board of Columbia Presbyterian Medical Center and Columbia University Health Sciences and the Bioethics National Committee for Re-search in the Dominican Republic approved the study. We obtained informed consent from the participant directly or from a family member (surrogate) when the individual had dementia.
Diagnosis A physician, typically a gerontologist, internist, or neurologist (RL, MM, RM), examined all patients and participating family members and obtained blood at the time of examination. To be included in the study, the proband and a living sibling were required to meet National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria for probable or possible AD [23] . These two definitions differ only by the allowance of features in persons with the diagnosis of possible AD that could have contributed to the dementia but were deemed not to be the primary cause (e.g., thyroid disease). The Clinical Dementia Rating Scale was used to rate disease severity [24] . Brain imaging and other laboratory studies were reviewed when they were available, and offered when medically required for diagnosis. The battery of neuropsychological tests used has been developed and evaluated extensively [25] [26] [27] . All diagnoses were established by a group of physicians and neuropsychologists at a consensus conference. Eleven patients died during the course of the study, and subsequent autopsies confirmed the clinical diagnoses in each person.
We used two definitions of affection status for analysis. First, we considered patients with the diagnosis of either possible or probable LOAD as "affected." In subsequent analyses, we attempted to reduce phenotypic heterogeneity by considering only the patients with the diagnosis of probable AD as "affected." For this analysis, individuals with possible AD were classified as unknown, which reduced the number of affected individuals by approximately 20%. For both definitions, individuals with other forms of dementia or mild cognitive impairment were also considered unknown for the purposes of analysis.
Age at onset For the current study, we conducted linkage analysis using age at onset of symptoms of dementia. This variable was derived from a semistructured interview with the patient's informant. The spouse or offspring of the proband, usually the most knowledgeable concerning the proband or affected relative, was chosen as the informant and asked which of the following symptoms first appeared: changes in memory, language, behavior, or personality. When the information was available, we used the reported age at which the symptoms first appeared. When the informant was unavailable, we used the age at the date of examination when the diagnosis of AD was made. To be conservative, we used the age-at-onset phenotype of affected individuals only and treated the age-at-onset phenotype of unaffected individuals as unknown; however, we used the genotype data of all family members regardless of their affection status to maximize the genotype information.
Covariates Sex was included as a covariate because of the higher frequency of women than men surviving into old age. Education, as determined by the number of years of formal education including college, technical, or graduate school, was also included because low education is associated with AD [28] . [29, 30] . Genotyping for the PSEN1 Gly206Ala mutation, which we previously described as a founder mutation in this population, was performed as in Athan et al. [31] .
Statistical and genetic analysis To determine the effect of APOE genotype on the age at onset, we contrasted individuals by the number of the APOE-ɛ4 alleles (2, 1, or 0) using generalized estimating equations [32, 33] . This method allowed each family to be analyzed as a cluster and circumvented the problem of non-independence. We then adjusted for education and sex as covariates. Quality control procedures (i.e., non-paternity check, Mendelian errors, Hardy-Weinberg equilibrium, etc.) were described in detail in our earlier study [21] .
Two-point and multipoint analyses of microsatellite markers were conducted using the VC method implemented in SOLAR (version 2.1.4). In SOLAR, heritability is first estimated in a polygenic model, including covariates followed by the general pedigree VC approach developed by Amos [34] extended to use multipoint identity-bydescent estimates to localize quantitative trait locus (QTL) [35] . The VC model compares the likelihood under the null hypothesis of no additive genetic variance due to a QTL s 2 q against the alternative hypothesis that estimates the variance due to the QTL. Twice the difference in the natural log likelihood of these two models yields a test statistic that is asymptotically distributed as a 50:50 mixture of a χ 2 variable and a point mass of zero [35] . The maximum likelihood estimates of the allele frequencies were calculated using all marker data from the Caribbean Hispanic families. We corrected for ascertainment by designating probands and computing likelihoods conditional on the proband. Correction by exclusion of the initial proband has been found to be an effective means to correct ascertainment bias, and can improve power to detect linkage [36] .
Age at onset of dementia was analyzed as a continuous variable under two definitions as described above: either probable or possible AD as affected; then probable AD only. Genome-wide linkage analyses were limited to affected individuals and adjusted by education and sex as well as their product term. We then performed the analysis also allowing the incorporation of APOE-ɛ4 as an additional covariate.
For markers with a logarithm of odds (LOD) score of one or higher in the two-point analysis, we computed empirical p values to limit the possibility of false positives at a given marker, using the genotyping information and marker allele frequencies from the data to simulate genotypes under the assumption of no linkage. Each simulation consisted of 10,000 replicates. In each replicate, a fully informative marker, completely unlinked to the trait, was simulated, and the actual trait (age at onset) was then tested against the simulated genotype for the marker to estimate the likelihood of a false positive finding for the observed LOD score. All computations for empirical p values were conducted using SOLAR. We then conducted a second simulation study to determine the 5 and 1% genome-wide threshold LOD scores to take into account multiple testing arising from using multiple markers to cover the genome. The theoretical basis of empirical thresholds for this approach was discussed by Churchill and Doerge [37, 38] . Briefly, after indexing age-at-onset phenotype, the phenotype was shuffled and was randomly assigned. The genetic map, genotypes, and other covariates were not changed during the shuffling procedure. The shuffled age-at-onset phenotype was analyzed under the same model as in the original analysis. The shuffling and analysis procedure was repeated 100 times, and the maximum genome-wide LOD score was recorded. From the ordered 100 maximum LOD scores, we obtained the empirical thresholds for 5 and 1% significance.
Single-point family-based association was assessed using an additive genetic model with the null hypothesis of no linkage and no association, as implemented in FBAT version 1.7.3 [39, 40] . Allele frequencies were estimated by FBAT using the EM algorithm.
Results
Demographics Among the 1,161 family members in the 209 families, 65.9% were women (Table 1 ). There were approximately six individuals per family. The average age of onset was 73.3 years (SD=10.6; range=30-98 years), and 50.4% (n=585) of the participants met criteria for either probable or possible LOAD [23] . The majority (77%) of affected individuals met criteria for probable LOAD. In most families, there were two affected individuals but 43% of the families had three or more affected. In 7.4% of family members, no consensus diagnosis could be made or other forms of dementia were present. For these individuals, the phenotype was coded as unknown, but their genetic data were used to estimate allele frequencies and to establish identity by descent.
APOE The presence of APOE-ɛ4 had clear effects on the age at onset of LOAD (Table 1 ; Z FBAT =4.9, p=9.4×10 7 ). For example, individuals with the ɛ4/ɛ4 genotype had onset of symptoms approximately 5.5 years earlier than those with the ɛ3/ɛ3 genotype (69.1 vs 74.6 years, respectively) and 3.5 years earlier than those with the ɛ3/ɛ4 genotype (69.1 vs 72.6, respectively). After adjusting for age, sex, and education, APOE accounted for roughly 13% of the variability in age at onset in this dataset. Thus, separate analyses were performed taking into account the presence of APOE-ɛ4 in the VC linkage analyses.
Linkage analysis The most significant two-point LOD of 2.70 (p empirical =0.0025) for probable and possible AD was obtained at chromosome 7q36 with APOE adjustment (Supplemental Figs. 1 and 2 ; Table 2 ). Without APOE adjustment, the LOD score at this position significantly lowered to 1.95. Through all the analyzed markers, we observed that inclusion of APOE as covariate in the twopoint analysis resulted in increased LOD scores. Particularly, markers at 17q25, 14q32, and 5q15 yielded LOD scores of 2.58, 2.46, and 2.38, respectively (0.0016< p empirical <0.0064) under the APOE adjusted model.
We then repeated the two-point analysis using probable AD only ( Table 2) . As with the results from the previous analysis of probable and possible AD, the same four loci showed support for linkage. Under the model without APOE adjustment, the most significant linkage was observed at 5q15 with an LOD score of 2.72. Additional three loci, namely, 17q25, 14q32, and 7q36, showed suggestive linkage with LOD scores of 2.71, 2.60, and 1.77, respectively. With the APOE adjustment, the most significant LOD score of 3.11 was observed for 5q15, with a flanking marker at 5q22 reaching an LOD score of 2.18. The remaining three loci had elevated LOD scores of 2.94 for 17q25, 2.36 for 14q32, and 2.29 for 7q36.
Our simulation study that took into account multiple markers determined the empirical genome wide threshold for significant linkage to be LOD scores of 1.97 and 1.24 for 1 and 5% significance, respectively, for the definition of probable and possible AD. Therefore, the four candidate regions, namely, 5q15, 7q36, 14q32, and 17q25, reached the threshold for a genome-wide false positive rate of 1% in more than one model of the linkage analysis.
Because the marker at 14q32 yielded a significant LOD and is proximal to PSEN1, we screened one affected person from each family for a PSEN1 mutation, Gly206Ala, specific to Caribbean Hispanics [31] . From the screen, we identified six individuals with this mutation who had an average age at onset of 57 years. We then reanalyzed this region after removing the families with the Gly206Ala mutation to determine whether the linkage signal at 14q32 can be explained by these families with the mutation. For the probable and possible AD definition, LOD score at 14q32 increased from 2.46 to 2.93 for an APOE-ɛ4 adjusted analysis. When restricted to probable AD, the LOD score increased from 2.36 to 2.83 for an APOE adjusted analysis. These observations suggest that the observed linkage at 14q32 was unlikely to be related to the Gly206Ala PSEN1 mutation.
The multipoint analysis in general yielded stronger evidence for linkage when probable AD was considered affected, compared with when probable and possible AD was considered affected (Fig. 1a, b, and c) . For probable LOAD, the strongest evidence for linkage was observed at 5q15 (LOD=2.96 for unadjusted and 3.29 for APOE adjusted), followed by 7q36 (LOD 2.41 for unadjusted and 2.17 for APOE adjusted) and 17q25 (1.86 for unadjusted and 1.9 for APOE adjusted). Comparable, but somewhat weaker, LOD scores were observed for probable and possible AD. The highest LOD score was 1.97 (p= 0.0013) at chromosome 5q15, and when adjusted for the APOE-ɛ4 allele, the LOD score increased to 2.22 (p= 0.0007). The multipoint LOD scores for 7q36 and 17q25 were suggestive (1.75 to 1.92) and declined somewhat when adjusted for the effect of APOE-ɛ4.
Lastly, our family-based association analysis showed that marker g10693 at 17p13 was significant in both linkage analysis (p=0.009) and association analysis (p= 0.002). In addition, several markers showed significant evidence for association with age at onset ( Table 3) . The most significant results were obtained at markers AGAT113Z (13q, p<0.001), D12S297 (12q13, p<0.001), and D14S592 (14q23, p<0.001). Microsatellite marker D19S245, located close to APOE, showed a significant association (p=0.001) with age at onset.
Discussion
We report several candidate susceptibility loci for age at onset of AD phenotype based on a genome-wide search of Caribbean Hispanic families with multiple members affected with AD. These candidate loci include 5q15, 7q36.3, 14q32, and 17q25.1 based on the linkage analysis; 12q13, 13q33, and 14q23 based on the family-based association analysis; and 17q13 based on both. Of these, 7q36.3 and 14q32.12 had been identified in previous linkage and association studies.
With few exceptions [14, 17] , reports of genome-wide scans of familial AD have relied on the clinical diagnosis as the trait of interest [6] . However, Li et al. [15, 41] argued that the age at onset of disease is equally important because the "regulation of onset could make it possible to delay onset beyond an individual's normal life span." Indeed, allelic variation in APOE profoundly affects risk by lowering the age at onset of AD between 3 and 5 years with each copy of the ε4 variant [7, 9, 10] . The likelihood that variants in other genes could have similar effects on the Fig. 1 a- age at onset was strengthened by a study finding that as many as four additional loci contribute to the variance in age at onset of LOAD [13] . The ability to identify these genes depends not only on the number of such genes but also on the magnitude of their contribution to the age at onset. Naturally, gene identification would become increasingly difficult, as the number of genes grows larger and their effect size smaller. The past few years of research would support this view because a large number of loci have been implicated and are currently the subject of intensive investigation.
No single method is superior in identifying genetic factors underlying complex diseases; thus, we performed linkage and family-based associated analysis using the same set of 9.3-cM spaced microsatellite markers covering the entire genome. In our previous study of LOAD [21] , seven loci were identified with LOD scores greater than 2.0, but the highest LOD score was 3.1 at chromosome 3q28. In the current study of age at onset, we observed weak-to-modest linkage or association for several markers that were also significant in our previous study of AD linkage genome scan. These include 3p22, 4p15, 7p22, 14q23, and 17q25. In addition, we identified several markers that were not previously observed in the LOAD scan. Given that this is the first stage gnome scan, some of these may explain a component phenotype that results in alteration of age at onset, while others may turn out to be false positives. Further examination of these regions with additional markers and samples will clarify these findings.
We and others reported linkage signals at 14q23 and 14q32.12. Avramopoulos et al. [42] reported significant evidence for linkage near PSEN1 at 14q24 related to a phenotype that included psychosis, whereas we found a significant association with D14S592 at 14q23, located 5 cM away from the PSEN1 gene. Interestingly, the linkage signal remained strong after excluding the families carrying the Gly206Ala mutation in the PSEN1 gene, suggesting presence of additional genetic locus in this region. In addition, we and others [17] observed significant linkage at 14q32.12, which is some distance away (∼33 cM) from 14q24 and the PSEN1 gene. Kamboh et al. [43] , using the 909 AD cases obtained from the Alzheimer's Disease Research Center, reported that the variant at codon 17 (A>T) on the ACT gene may affect age at onset and severity Only markers with LOD score above threshold of 1 are shown.
of AD. It is of interest to note that this variant is located 3 Mb away from D14S617, and this marker had LOD>2 under all four linkage models in the current study. We found suggestive evidence of linkage at 7q36.3 that deserves further investigation. Previously, Rademakers et al. [18] reported that LOAD phenotype was linked to 7q36. In one family, they identified a mutation in PAX transcription activation domain-interacting protein, but it is unclear as to the role of this gene in LOAD. Because the highest LOD score on 7q36 was obtained from the most distal marker, additional markers will need to be examined to exclude the possibility of a false positive result.
The family-based association tests revealed two chromosomal regions, 12q13 and 14q23, that have been reported in literature as the chromosomal regions that may harbor genes contributing to AD. In addition, marker g10693 at 17p13 was found to be significant under both linkage and association. The convergence of the two complementary strategies provides further support for considering this locus as a candidate region.
We observed only modest overlap between linkage and association results. This is not a contradiction in that linkage and association are techniques that examine two somewhat different but related phenomena. Linkage analysis tests the cosegregation of the disease and marker loci within families without reference to any specific allele. Association investigates the co-occurrence of alleles with disease. It is possible to observe an allelic association without evidence of linkage, especially when allele frequency is high. Moreover, association between marker alleles and disease locus can be maintained by factors other than linkage such as demographic history, population admixture, recent mutation, or inbreeding. When a disease-associated allele explains only a small portion of the variance, although it occurs more often in affected individuals, power for linkage analysis can be limited [5] . In these situations, family-based association analyses can provide addition statistical power [44] . Therefore, linkage and association tests may be used as complementary approaches when identifying susceptibility loci underlying complex traits.
Several reasons may explain the lack of signal near the APOE locus in our linkage analysis. It has been reported that APOE explains only 4% of the age at onset variability in familiar AD [45] making it difficult to detect. Second, microsatellite markers, spaced at an average distance of 9 cM in a genome-wide search, may not have insufficient marker information content for mapping, thereby further reducing statistical power. In addition, the frequency of the ɛ4 allele in this set of FAD was approximately 30%, indicating that approximately 50% of the individuals will have homozygous genotypes. As a result, power for linkage analysis at this locus will be reduced, as co-segregation of a putative allele with disease will be difficult to detect. When using family-based association tests, however, we observed modest support for association with D19S245, located approximately 10 cM away from the APOE locus. In a recent paper, Coon et al. [46] demonstrated that the APOE locus as a susceptibly locus for LOAD was identified when they saturate the genome with more than 300,000 SNP markers.
The findings in this analysis are distinct from those in the previous investigations of age at onset. One of the main reasons for differences is the fact that the current study examines familial AD based on Caribbean Hispanic ethnicity, while others primarily used Caucasians of European descents. Moreover, each study highlighted different loci for regions harboring susceptibility loci. Olson et al. [17] observed evidence for an interaction between 20p12.2 and the APP region (21q21), limited to the oldest age group and to those lacking APOE-ɛ4 alleles. This finding has been supported in follow-up analyses [47] , but we found no evidence for linkage in that region. The closest marker showing any relation to age at onset in our dataset was at 20q13.2 (LOD ranging from 1.06 to 1.15; p= 0.015). Li et al. [15, 41] combined individuals with AD and Parkinson's disease to identify loci related to age at onset. Loci near chromosome 10q24.32 provided the maximum LOD score, and in a later study [41] , these investigators found that single-nucleotide polymorphisms in glutathione S-transferase omega-1, GSTO1, were associated with this phenotype. However, other studies have not confirmed this association thus far [48] [49] [50] . We did not find evidence for linkage for GSTO1 at 10q26.12 for the age-at-onset phenotype, but found weak evidence for linkage with the AD phenotype [22] . Holmans et al. [14] performed an affected sib-pair linkage analysis with age at onset, and observed the strongest support for linkage at chromosome 21q21, which was previously reported by Olson et al. [17] . In our dataset, locus 21q22 yielded a modest LOD score of 1.08.
No previous study has reported 5q15, 17q25, 13q, or 17p13 as loci harboring susceptibility genes influencing age at onset of familiar late onset AD. Among the most interesting candidate genes underlying the linkage peak at 5q15 is calpastatin (CAST, 5q15-q21). Calcium-dependent proteases, calpains, may be involved in the pathogenesis of neurodegenerative diseases such as AD by participating in excitotoxic stress-induced [51, 52] . CAST is a specific natural inhibitor of calpain and can alter neuritic degeneration in rodent models of AD. At 17q25, in addition to two members of the G-protein-coupled receptor family, galanin receptor 2 (GALR2) is located. GALR2 is expressed in the hypothalamus and hippocampus, and is involved primarily in signaling through the phospholipase C/protein kinase C pathway. Fathi et al. [53] demonstrated that GALR2 coupled efficiently to both the Gq and the Gi proteins to simultaneously activate two independent signal transduction pathways. At 17p13 region, MYH8 and TM4SF5 genes could be considered as possible candidate genes because their expression is significantly downregulated in hippocampus in AD brain [54] .
Age-at-onset linkage analysis suggests that several candidate loci (5q15, 17q25.1, 14q32, and 7q36.3) deserve further investigation, and 7q36.3 and 14q32.12 had been identified in previous linkage studies. In addition, familybased association analysis identified 12q13, 13q33, and 14q23 as candidate regions. Some of these may harbor susceptibility genes that explain a component phenotype of AD which results in alteration of age at onset, while others may turn out to be false positives. Given the support for linkage, association, or both at these loci in the current study, further examination of these loci with additional markers and samples is necessary to better understand the role of these loci on age at onset of AD.
